Kamada Reports Fiscal Year and Fourth Quarter 2021 Financial Results; Provides Revenue and Profitability Guidance with Significant Growth Expected in 2022
March 15, 2022 07:00 ET
|
Kamada Ltd.
Total Revenues for Fiscal Year 2021 were $103.6 Million and Fourth Quarter 2021 Revenues were $31.5 Million. Fiscal Year 2022 Revenues are Expected to Range Between $125 Million to $135 Million,...
Kamada Expands U.S. Leadership Team with Two Key Appointments
March 14, 2022 08:00 ET
|
Kamada Ltd.
REHOVOT, Israel, March 14, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty plasma-derived...
Kamada to Announce Fourth Quarter and Fiscal Year Ended December 31, 2021 Financial Results, and Host Conference Call on March 15, 2022
March 02, 2022 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, March 02, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kamada Announces Strategic Transformational Transaction Positioning the Company as a Global Leader in the Plasma-Derived Hyperimmune Market Through the Acquisition of a Portfolio of Four FDA-Approved Commercial Products
November 22, 2021 07:05 ET
|
Kamada Ltd.
2021 Global Revenue of the Portfolio Acquired from Saol Therapeutics is Estimated Between $40 Million to $45 Million, with Approximately 75% and 20% of Sales Generated from U.S. and Canada,...
Kamada Reports Third Quarter and First Nine Months of 2021 Financial Results, and Strategic Transformational Acquisition of a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune Commercial Products
November 22, 2021 07:00 ET
|
Kamada Ltd.
Third Quarter 2021 Revenues were $23.0 Million and Total Revenues for the First Nine Months of 2021 were $72.2 MillionKamada has Acquired a Portfolio of Four FDA-Approved Plasma-Derived Hyperimmune...
Kamada to Announce Third Quarter Financial Results and Host Conference Call on November 22, 2021
November 08, 2021 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kamada Reports Second Quarter and First Half 2021 Financial Results, Recent Achievements and Corporate Development Activities
August 11, 2021 07:00 ET
|
Kamada Ltd.
Second Quarter 2021 Revenues were $24.2 MillionIn Connection with the Transition of GLASSIA® Manufacturing, Kamada Largely Completed a Workforce Downsizing in the Second Quarter that will Result in an...
Kamada to Announce Second Quarter and First Half 2021 Financial Results and Host Conference Call on August 11, 2021
August 05, 2021 07:00 ET
|
Kamada Ltd.
REHOVOT, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived biopharmaceutical company, today announced that it will release financial results for the...
Kedrion and Kamada Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children
June 02, 2021 07:00 ET
|
Kamada Ltd.
Label Expansion Differentiates KEDRAB® as the First and Only Human Rabies Immune Globulin (HRIG) Available in the U.S. to be Clinically Studied in ChildrenKEDRAB Product Label Now Includes Patients of...
Kamada Reports First Quarter 2021 Financial Results, Recent Achievements and Corporate Development Activities
May 12, 2021 07:00 ET
|
Kamada Ltd.
First Quarter 2021 Revenues were $24.9 Million, and Adjusted EBITDA was $3.7 MillionIn Connection with the Transition of GLASSIA® Manufacturing, the Product’s U.S. Biologics License Application will...